Free tool
FAERS Monitor: Venofer
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021135 or its brand name (Venofer, Iron Sucrose). Reports on generic versions are filed under their own applications.
Reports
9,664
Serious
7,633
79% of reports
Hospitalization
3,293
Death reported
935
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity1,169
- nausea1,035
- dyspnoea1,014
- off label use654
- pruritus651
- vomiting647
- diarrhoea554
- rash550
- hypotension530
- dizziness520
- urticaria495
- headache473
- malaise464
- infusion related reaction462
- arthralgia459
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 48 |
| 2005 | 68 |
| 2006 | 86 |
| 2007 | 141 |
| 2008 | 157 |
| 2009 | 270 |
| 2010 | 240 |
| 2011 | 190 |
| 2012 | 269 |
| 2013 | 299 |
| 2014 | 277 |
| 2015 | 384 |
| 2016 | 444 |
| 2017 | 420 |
| 2018 | 485 |
| 2019 | 843 |
| 2020 | 589 |
| 2021 | 690 |
| 2022 | 904 |
| 2023 | 814 |
| 2024 | 716 |
| 2025 | 704 |
| 2026 | 626 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,044,495 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 462 | 15.3 | 14.0 | 6,123 |
| drug hypersensitivitySignal | 1,169 | 13.2 | 12.5 | 13,236 |
| urticariaSignal | 495 | 6.4 | 5.9 | 2,284 |
| hypotensionSignal | 530 | 5.8 | 5.3 | 2,096 |
| dyspnoeaSignal | 1,014 | 3.9 | 3.7 | 2,244 |
| pruritusSignal | 651 | 3.7 | 3.4 | 1,296 |
| vomitingSignal | 647 | 3.0 | 2.8 | 878 |
| nauseaSignal | 1,035 | 2.8 | 2.7 | 1,287 |
| rashSignal | 550 | 2.7 | 2.5 | 622 |
| arthralgiaSignal | 459 | 2.4 | 2.2 | 382 |
| malaiseSignal | 464 | 2.3 | 2.1 | 348 |
| dizzinessSignal | 520 | 2.3 | 2.1 | 377 |
| diarrhoea | 554 | 1.9 | 1.7 | 230 |
| headache | 473 | 1.6 | 1.5 | 122 |
| off label use | 654 | 1.6 | 1.5 | 164 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.